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Abstract
Background: Elevated levels of circulating matrix metalloproteinase-9 (MMP-9) have been demonstrated in patients with
established coronary artery disease (CAD). The aim of this study was to analyse levels of MMP-9 in a population free from
symptomatic CAD and investigate their associations with cardiovascular (CV) risk factors, including C-reactive protein (CRP).
Methods: A cross-sectional study was performed in a population based random sample aged 45–69 (n=345, 50% women).
MMP-9 levels were measured in EDTA-plasma using an ELISA-method. CV risk factors were measured using questionnaires
and standard laboratory methods.
Results: Plasma MMP-9 was detectable in all participants, mean 38.9 ng/mL (SD 22.1 ng/mL). Among individuals without
reported symptomatic CAD a positive association (p,0.001) was seen, for both men and women, of MMP-9 levels regarding
total risk load of eight CV risk factors i.e. blood pressure, dyslipidemia, diabetes, obesity, smoking, alcohol intake, physical
activity and fruit and vegetable intake. The association was significant also after adjustment for CRP, and was not driven by
a single risk factor alone. In regression models adjusted for age, sex, smoking, alcohol intake and CRP, elevated MMP-9 levels
were independently positively associated with systolic blood pressure (p=0.037), smoking (p,0.001), alcohol intake
(p=0.003) and CRP (p,0.001). The correlation coefficient between MMP-9 and CRP was r=0.24 (p,0.001).
Conclusions: In a population without reported symptomatic CAD, MMP-9 levels were associated with total CV risk load as
well as with single risk factors. This was found also after adjustment for CRP.
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Introduction
It is today widely accepted that inflammatory processes are
involved in plaque rupture preceding acute coronary events [1,2].
In particular, pro-inflammatory cytokines and acute phase
reactants including C-reactive protein (CRP), have been used as
biomarkers and predictors for acute coronary syndromes (ACS)
[3–6]. In parallel, pro-inflammatory cytokines such as interleukin-
1 (IL-1) and tissue necrosis factor-a (TNF-a) have been shown to
up-regulate matrix metalloproteinase-9 (MMP-9) [7,8]. MMP-9 is
considered to be a key determinant of extracellular matrix
degradation, having collagen as the main substrate. It is to date
the most studied enzyme in the MMP-family regarding cardio-
vascular diseases. Increased concentrations and activity of MMP-9
have been observed in human atherosclerotic vulnerable plaques
with high inflammatory activity [9–12], suggesting a role in matrix
degradation and plaque rupture.
So far, most studies exploring elevated levels of MMP-9 and its
association to coronary artery disease (CAD) have been based on a
experimental or clinical design, the latter showing elevated levels
of plasma MMP-9 in patients with CAD [13–18]. While there is a
number of experimental or cross-sectional studies in selected
populations that associates elevated levels of MMP-9 to CAD risk
factors before onset of disease e.g. smoking [19], alcohol [20], and
hypertension [21,22], little is still known about the distribution of
MMP-9 in the general population. In a population-based study in
the Framingham cohort, MMP-9 could be detected in plasma in
only 20% of the participants, thus suggesting that MMP-9 was
unlikely to be an informative biomarker in a low-risk population
[23].
In the present study, we hypothesized that circulating levels of
MMP-9 were independently related to cardiovascular risk factors,
before onset of ACS. The aim with the study were divided into
three steps: 1) To test the association of levels of MMP-9 and a
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pressure, dyslipidemia, diabetes, obesity, smoking, alcohol intake,
physical activity and fruit and vegetable intake. 2) To test the
association of levels of MMP-9 and each of the risk factors
mentioned. 3) To evaluate the associations above after adjustment
for CRP. In addition, analyses were adjusted for Tissue Inhibitor
of Metallo Proteinase-1 (TIMP-1), one endogenous inhibitor of
MMP-9.
Methods
Study population and design
Participants were recruited from the Life conditions, Stress and
Health (LSH) study, a population based study, aiming at testing if
psychobiological pathways mediate the association between socio-
economic status and incident cardiovascular disease [24]. It was
conducted in the county of O ¨ stergo ¨tland in the southeast of
Sweden, with the study base defined as the population living in the
catchment area for any of the ten collaborating Primary Health
Care Centres (PHCC’s). Participants were evenly distributed by
sex and age, ranging from 45 to 69 years at enrolment. Exclusion
criteria were self-reported severe disease that hindered the
possibility to participate, e.g. terminal cancer, severe dementia
and psychiatric disorders. Data collection was conducted in late
2003 and early 2004, constituted by a brief health examination,
collection of blood samples and questionnaires. Participants with
clinical symptoms of infection were instructed to come back to a
PHCC after recovery.
The response rate for the initial baseline was 62.5%. The
sample was representative for the population in terms of
educational attainment, employment rates and immigrant status.
The study design was approved by the ethical committee of the
medical faculty, Linko ¨ping University, and written consent was
obtained from all participants.
402 individuals, randomly chosen within the first 1 000
participants in the LSH-study were included in this sub-study,
without any stratification criteria such as sex, age or other
properties.
There was no potential conflict of interest for the authors or
funders of this study.
Data from the physical examinations
All nurses collecting data were trained together and the
laboratory equipment used was calibrated to ensure standardiza-
tion. The participants came to the PHCC’s in the morning to
minimize effects of diurnal variation, all in a fasting state. Heart
rate, systolic and diastolic blood pressure (SBP and DBP) were
measured in a sitting position in two minutes interval after five
minutes of rest, using the mean of second and the third
measurement (Omron M5-1 digital). Weight, height and waist-
hip measures in standing position were collected. Plasma glucose
(HemoCue), triglycerides and lipids (ADVIA 1650) were analysed
directly after sample collection and LDL-cholesterol was calculat-
ed using Friedewalds formula [25]. For full information on data
collection, see Hollman and Kristenson [24].
Biochemical analyses
The concentrations of MMP-9 and tissue inhibitor of metallo-
proteinase 1 (TIMP-1) were measured in EDTA-plasma [26], by
human Biotrak ELISA systems (Amersham Biosciences, Uppsala,
Sweden). The assay for MMP-9 measures MMP-9, Pro-MMP-9
and the ProMMP-9/TIMP-1 complex. The lower detection limit
was 0.6 ng/mL, interassay coefficient of variance (CV) was 7.2 to
7.9%. TIMP-1 was measured in half of the participants (n=201),
The assay recognises free TIMP-1 and TIMP-1 complexed with
MMPs, with a lower detection limit of 1.25 ng/mL and a CV of
6.8%. C-reactive protein (CRP) was measured in serum by a
highly sensitive latex-enhanced turbidimetric immunoassay
(Roche Diagnostics GmbH, Vienna, Austria) with a lower
detection limit of 0.03 mg/L and CV of 1.7%. Aliquotes of
plasma and serum (0.5 mL) were stored in 270u Celsius
approximately 18 months before laboratory analysis.
The analyses were performed in two steps, where preliminary
statistical analyses were performed on half of the participants
(n=201), before deciding if analysis should be performed on the
entire sub-sample.
Data from questionnaires
The participants responded to a questionnaire including
questions on smoking, alcohol intake, physical activity, fruit and
vegetable intake, ongoing medication and self-reported medical
diagnoses. To measure symptomatic CAD, the question ‘‘Have
you ever had any event of myocardial infraction or angina pectoris
diagnosed by a medical doctor? (Yes/No/Don’t know)’’ was used.
A similar construct was used to capture self-reported diabetes.
Alcohol intake was based on a food frequency questionnaire
adopted from the Swedish Mammography Cohort [27], combin-
ing frequency and typical amounts of different beverages. The
intake of fruit and vegetables utilized the same food frequency
questionnaire [27], wherefrom a sum score of gram fruit and
vegetables per day was calculated. The participants were divided
into three subgroups: low intake (less than mean minus one SD),
moderate (mean plus/minus one SD) and high intake (more than
mean plus one SD). The measurements of physical activity were
adopted from the population surveys conducted by the Public
Health Science Centre in the county of O ¨ stergo ¨tland. Two
questions regarding daily activity were combined into an index
with four categories: inactive, low, moderate and high level of
physical activity [28]. Smoking and alcohol intake were quantified,
whereas the subgroups stratified on fruit and vegetable intake and
physical activity, respectively, were used as ordinal categories, as
attempts to quantify to any further extent would be based on
assumptions that cannot be validated in our data set.
Statistical analysis
Circulating levels of MMP-9 was set as the main outcome
measure. As previous CAD event might elevate levels of MMP-9
[13–18], and statins might lower levels of MMP-9 [29,30],
participants with a self-reported history of CAD and participants
using hypolipidaemic drugs were excluded from the analyses. The
analysis were principally divided into three steps: 1) In regression
models, total risk load was tested, using dichotomies of the eight
risk factors blood pressure, LDL/HDL-ratio, diabetes, obesity,
smoking, alcohol intake, physical activity and fruit and vegetable
intake. To ensure that the association was not driven by a single
risk factor alone, risk load models excluding one risk factor at a
time were tested as well. 2) Studying single risk factors, linear
regression models adjusting for age and sex were performed on SD
increment based on SD within the study population for each
independent variable. Multivariate regression models adjusting for
age, sex and variables with highly significant associations to MMP-
9 in univariate analyses (p,0.001) were performed in addition. 3)
Both the total risk load model and the regression models on single
risk factors were performed with and without adjustment for CRP.
Separate models for men and women were also performed for all
associations studied. In a sub-sample (n=172) additional adjust-
ment for Tissue Inhibitor of Metallo Proteinase-1 (TIMP-1) were
MMP-9 and CV Risk Factors
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MMP-9.
Aiming at minimizing bias of reversed causation, participants
that reported they recently had changed their behavior due to
health related problems were excluded when calculating means for
behavioral risk factors. In regression models participants that
recently had quit smoking or recently had reduced alcohol intake
were categorized as top ordinal category. However, questionnaires
where not specific enough to perform this action regarding
physical exercise or fruit and vegetable intake.
A 2-sided probability value of p #0.05 was considered as
statistically significant. ANOVA-analyses were used to outline any
significant differences over ordinal categories, t-tests were used in
dichotomies.
Analyses were performed in STATA statistical software, release
6.0, Stata Corporation, and SPSS for Windows statistical software,
release 14.0.2, SPSS Inc.
Results
Clinical characteristics and plasma MMP-9 levels
MMP-9 could be detected in all participants (n=402). In total,
the mean for MMP-9 was 40.2 ng/mL with a range from 2.9 to
246.1 ng/mL (SD=26.7), and no difference of mean level
between the first (n=201) and the second (n=201) run of analyses
(p=0.491). There were significantly higher levels of MMP-9 in the
subgroup with self-reported CAD (n=16) compared to partici-
pants without reported symptomatic CAD (mean: 52.7 (SD 34.5)
vs 38.7 (SD 22.1) ng/mL, p=0.017). To allow for analysis on
participants without symptomatic CAD, this sub-group (n=16)
was excluded in further analyses along with participants unsure of
diagnosis and missing values on self reported CAD (n=21).
Further, the associations of MMP-9 with use of hypolipidaemic
and antihypertensive agents, respectively, were tested in regres-
sions adjusting for sex, age and CV risk factors. As there were a
significant association with hypolipidaemic drugs (n=20, beta in
regression when adjusting for age, sex and risk factors: 211.9 ng/
mL, p=0.023), these participants were excluded. No significant
association could be seen for antihypertensive drugs (p=0.294),
why participants on such medication were kept in the analyses.
After all exclusions (previous self-reported CAD diagnosis and use
of hypolipidaemic drugs), 345 participants remained. Their
clinical and laboratory characteristics are shown in Table 1. The
mean of MMP-9 in the remaining group was 38.9 ng/mL with a
range from 2.9 to 143.9 ng/mL (SD 22.1). In univariate analysis,
women (n=175) had significantly lower mean of MMP-9 than
men (n=170) (34.7 ng/mL vs 43.2 ng/mL, p,0.001). No
significant trend could be seen over age.
Relations between plasma MMP-9 levels and total load of
risk factors
An analysis of MMP-9 levels over total risk load was performed,
presented in Figure 1. There were 326 participants with
information in all of the eight risk factors included. We found a
highly significant association between plasma MMP-9 levels and
number of risk factors added (+5.7 ng/mL (95% CI 3.6;7.7) per
additional risk factor. p,0.001). The findings were persistent
when divided by sex (not shown in figure, men n=157 p=0.005,
women n=167 p,0.001). After adjustment for CRP, the
association between level of MMP-9 and number of risk factors
Table 1. Characteristics of study sample, n=345.
Men (n=170) Women (n=175)
Clinical and laboratory characteristics Age (yrs) 56.467.2 56.467.2
BMI (kg/m
2) 27.163.9 26.064.7
waist circumference (cm) 97.6610.7 84.3611.7
Diabetes (%) 7.7 (n=13) 5.2 (n=9)
SBP (mm Hg) 135.0618.2 128.2620.0
DBP (mm Hg) 85.1611.7 82.0611.3
Antihypertensive treatment (%) 14.7 (n=25) 13.7 (n=24)
Heart rate (bpm) 64.5610.7 68.269.8
Total cholesterol (mmol/L) 5.560.9 5.660.9
LDL (mmol/L) 3.560.9 3.460.8
HDL (mmol/L) 1.460.3 1.760.3
LDL/HDL cholesterol ratio 2.560.7 2.160.6
Triglycerides (mmol/L) 1.560.9 1.160.6
CRP (mg/L) 0.8 (0.2–2.1) 0.7 (0.2–1.9)
TIMP-1 (ng/mL) 288.2 (254.2–314.8) 268.9 (244.9–300.3)
Behavioral characteristics Smoking (%) 17.9 (n=30) 15.7 (n=27)
Drinking (%) 15.3 (n=26) 2.9 (n=5)
High level of physical activity (%) 16.2 (n=27) 19.0 (n=33)
High fruit intake (%) 8.3 (n=14) 12.6 (n=22)
Outcome measures Detectable MMP-9 (%) 100 100
Plasma MMP-9 (ng/mL) 43.2624.2 34.7619.1
Participants with reported symptomatic CAD and participants using statins are excluded. Analysis on TIMP-1 performed on a sub-sample, n=172. All values are
mean6SD or percentages, except CRP and TIMP-1, expressed as median and interquartile range.
doi:10.1371/journal.pone.0001774.t001
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risk factor. p,0.001), with persistent findings when divided by sex
(men p=0.004, women p=0.001). Adjusting for TIMP-1 in a sub-
analysis did not alter the results, as there neither was any
significant association between TIMP-1 and total risk load
(p=0.576) nor between TIMP-1 and MMP-9 (p=0.972).
Further, the association to the total risk load was not driven by a
single risk factor. When removing one risk factor at a time from
the total risk load, the associations between risk load and MMP-9
were highly significant (p,0.001) in all eight models tested,
regardless of adjusting for CRP or not.
Relations of levels of MMP-9 and single risk factors
Distribution of MMP-9 over ordinal categories of the behavioral
risk factors smoking, alcohol intake, fruit and vegetable intake and
physical exercise are presented in figure 2. There were significant
differences of MMP-9 levels between the ordinal categories of all
four factors tested. The smoking group reported a mean of 12.7
cigarettes per day (SD 6.5 cigarettes per day). The reported mean
alcohol intake in the ordinal categories were 34.g/week (SD 29 g/
week), 138 g/week (SD 14 g/week) and 270 g/week (SD 313 g/
week), respectively. Regression models are presented in table 2.
Adjusting for age and sex, level of MMP-9 was significantly
associated to the single risk factors waist circumference, SBP, heart
rate, low HDL, triglycerides and CRP apart from each of the four
behavioral factors tested. When adjusting for age, sex and CRP
(data not shown), level of MMP-9 was significantly to SBP,
triglycerides, each of the four behavioral factors tested and CRP.
In multivariate analyses adjusting for age, sex, smoking, alcohol
intake and CRP, level of MMP-9 was independently associated
with SBP, smoking, alcohol intake and CRP, respectively.
The partial correlation between MMP-9 and CRP (adjusting for
age and sex) was r=0.17 (n=335) p,0.001. After exclusion for
acute ongoing inflammation (CRP.10 mg/L) the coefficient was
still fairly low, r=0.24 (n=329) p,0.001.
Discussion
The main finding in this study is that there was a highly
significant correlation between plasma levels of MMP-9 and total
load of CV risk factors, in a population-based sample without
reported symptomatic CAD. The association found was not driven
by one single risk factor alone, and the trend remained significant
after additional adjustment for CRP and TIMP-1. Furthermore,
significant associations of MMP-9 levels were found with the risk
factors SBP, smoking, alcohol intake and CRP in a multivariate
regression.
A noteworthy difference from earlier studies was that plasma
levels of MMP-9 were detectable in all participants. This could
possibly be due to a relatively short period of time passing between
sample date and analysis, as MMP-9 has been shown to degrade
even at low temperature [31]. Although the ELISA technique
were slightly different, a comparison of our results with the
Framingham study [16] is appropriate as the population
characteristics according to traditional risk factors (as shown in
Table 1) were in the same range in both studies. As MMP-9 could
be detected in only 20% of the participants in the Framingham
study [16] (using a 2-site sandwich ELISA assay with a detection
level of 4 ng/mL), it was concluded that MMP-9 was unlikely to
be an informative biomarker in a low-risk population. Our
findings, based on 100% detection, may indicate an altered
conclusion. The data thus supports the idea that elevated levels
plasma levels of MMP-9 before onset of disease may reflect an
ongoing remodelling and early pathogenesis of the arterial wall
and/or a low-grade systemic inflammation.
There is a current discussion on the use of novel biomarkers for
cardiovascular risk stratification. In that light, the low but
significant correlation between CRP and MMP-9 is of particular
interest in our findings. This implies that CRP and MMP-9, at
least to some extent, could be markers of different physiological
pathways. This assumption was strengthened by the finding that
total risk load and single risk factors remain significant when
Figure 1. MMP-9 in relation to total risk load. Dichotomies of eight risk factors are taken into account in the analysis: n=326 with full
information on every variable. Blood pressure (SBP.160 and/or DBP.100 mm Hg and/or using antihypertensive agents, n=81), LDL/HDL (ratio .3,
n=54), obesity (BMI.30, n=67), diabetes (yes, n=22), smoking (yes, n=57), alcohol intake (.170 grams/week, n=37), low physical activity (all other
than top ordinal category, n=272), low fruit and vegetables intake (all other than top ordinal category n=307). Mean and 95% confidence intervals.
doi:10.1371/journal.pone.0001774.g001
MMP-9 and CV Risk Factors
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MMP-9 as a biomarker gives partly other information apart from
redundant information of CRP measurements. Plausible pathways
of potential interest for MMP-9 regulation such as antioxidant/
oxidant imbalance [32,33] and/or influences of different hor-
mones (stress [34] and sex [35,36]) should be further investigated.
Given the participation rate and the exclusion criteria
constituted of self-reported diagnoses and use of hypolipidaemic
drugs, the population tested is supposedly driven by a selection
towards a healthy population. Such a selection would not distort
the main findings in this study, as the selection if having any
impact, would weaken the associations tested. It should be noted
however that the interpretation relies on self-reported data. The
agreement between self-reported diagnosis and medical record of
myocardial infarction has been demonstrated to be high, both in
terms of specificity and sensitivity [37], but as the participants were
not examined invasively in this study, the presence of significant
CAD cannot be excluded.
The major limitation with this study is that, whereas the
association to total risk load was stable regardless of model used,
the power may not be sufficient enough to fully evaluate the
associations to single risk factors. While we found a number of
associations shown in table 2, the inter-relation between the
coefficients are hard to fully interpret, due to a limited number of
participants. This is in particular the case when including several
risk factors into the multivariate analyses. It should for instance be
noted that smoking and alcohol intake, the behavioral factors that
remained significant in a multivariate analysis, were highly
clustered to other risk factors. Only a handful of participants
(n=5) had smoking or alcohol intake as the only present
behavioral risk factor. In most of the participants, these factors
appeared in combination with at least one of the other tested risk
factors. Hence, it cannot be excluded that an effect from e.g. low
physical activity and/or low fruit and vegetable intake as found in
the crude analysis would be hidden in a multivariate analysis due
to co-variation to alcohol and smoking.
Further, the only variables that did not reach significance or
close to significance when adjusting for age and sex were total
cholesterol, LDL, LDL/HDL ratio and diabetes. On one hand, it
has been suggested before that MMP-9 does not reflect the lipid
profile [38]. On the other hand the variation in the lipid profile
variables is likely to be truncated by the exclusion criteria and the
selection towards a healthy population. Diabetes relied on self-
reported data, why interpretation should be done with cautious-
ness.
Another limitation could be that data on genetic polymorphisms
is not included in the data set. Genetic polymorphisms could at
least partially explain the variance found in the distribution of
MMP-9 at individual level [13], and should be considered in
further analyses.
Some authors have suggested that including/adjusting for
TIMP-1 would enhance the physiologic information of MMP-9
[22,39,40]. Thus we tested this in a randomly selected sub-sample
(n=201). However, in this sub-sample the addition of TIMP did
not change the associations between MMP-9 and total risk load,
thus we did not perform TIMP-analyses in the remaining plasma
samples.
In conclusion we found that in a population without reported
symptomatic CAD, MMP-9 levels were associated with total CV
risk load as well as with single risk factors. This was found also
after adjustment for CRP. The participants will be followed
prospectively for CAD events and thus it will be possible to
investigate the importance of MMP-9 as a marker for future
cardiovascular risk.
Figure 2. MMP-9 in relation to ordinal categories of smoking, alcohol intake, fruit and vegetable intake and physical exercise,
respectively. Mean and 95% confidence intervals.
doi:10.1371/journal.pone.0001774.g002
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SBP (19 mm Hg) 2.9 (0.4;5.4) 0.022 3.0 (0.6;5.5) 0.014 2.5 (0.1;4.9) 0.037
DBP (12 mm Hg) 2.1 (20.2;4.5) 0.075 2.0 (20.3;4.3) 0.092 1.5 (20.8;3.8) 0.189
Heart rate (10.4 bpm) 2.7 (0.3;5.1) 0.024 0.7 (21.6;3.2) 0.518 20.3 (22.7;2.1) 0.806
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